Senior Director, Global Commercial Development

Revolution Medicines

2d•$232,000 - $290,000•Remote

About The Position

Revolution Medicines is seeking a Senior Director to lead global commercial strategy and lifecycle development for its pancreatic cancer portfolio, including daraxonrasib, zoldonrasib, and future pipeline candidates. The role spans potential opportunities in first-line metastatic, locally advanced, perioperative, and adjuvant disease, as well as future indications. Reporting to the Executive Director, Global Commercial Development – Pancreatic Cancer, this leader will translate evolving clinical evidence, patient and biomarker insights, and competitive dynamics into integrated global strategies, portfolio investment recommendations, and stage-appropriate launch readiness. The position requires strong cross-functional leadership and alignment with existing asset and indication teams. The Senior Director will evaluate indication and lifecycle opportunities, develop treatment-setting strategies, shape asset and combination positioning, and lead patient and market forecasting. The role will work across Clinical Development, Medical Affairs, HEOR, Market Access, Precision Medicine, Diagnostics, regional affiliates, global brand teams, and other partners to inform development, biomarker strategy, customer engagement, commercialization, and launch planning. The role also guides cross-functional teams and external partners, communicates with senior leaders and governance forums, and monitors market and scientific developments. Up to 40% travel is required. The position is listed as full-time. The stated base salary range for candidates working onsite at the Redwood City, California headquarters is $232,000–$290,000 USD; the range is adjusted for local market and individual factors. The company also describes competitive cash compensation, equity awards, benefits, and learning and development opportunities.

Requirements

Bachelor’s degree and at least 15 years of progressive commercial experience, or an advanced degree and at least 8 years of progressive commercial experience, in a biotechnology and/or pharmaceutical company.
Commercial experience including strategic marketing; sales experience is considered ideal.
Proven success developing global oncology commercial strategies across products, indications, or stages of disease and influencing complex cross-functional product teams.
Ability to develop patient and revenue forecasts, interpret market and clinical insights, and evaluate strategic trade-offs that inform portfolio investment decisions.
Strong leadership skills and ability to build high-performing teams and partnerships and influence without direct authority.
Excellent organizational and prioritization skills, including the ability to deliver high-quality strategic work under evolving timelines.
Strong clinical and scientific acumen and ability to translate emerging clinical evidence, trial design, and oncology treatment pathways into commercial implications.
Excellent executive communication, presentation, and external stakeholder engagement skills.
Entrepreneurial mindset, comfort with ambiguity, and commitment to improving outcomes for people with cancer.

Nice To Haves

Experience in pancreatic or other gastrointestinal cancers, including first-line metastatic and earlier-stage treatment settings.
Experience with precision oncology, KRAS/RAS-targeted medicines, molecular testing, or biomarker-defined patient populations.
Experience developing global commercial strategies for oncology launches, indication expansion, or lifecycle management.
Familiarity with oncology care pathways and patient journeys in pancreatic cancer.
Experience in a rapidly growing biotechnology company and partnering with global and regional commercial organizations.

Responsibilities

Lead integrated global commercial development strategy for the pancreatic cancer portfolio across therapeutic and disease settings, connecting indication strategies to overall portfolio value.
Evaluate clinical and commercial opportunities, unmet need, competitive differentiation, treatment sequencing, and investment trade-offs; make recommendations for development and governance decisions.
Develop differentiated commercial hypotheses for first-line treatment, locally advanced disease, surgical and perioperative pathways, and adjuvant therapy.
Partner with product teams to shape complementary daraxonrasib and zoldonrasib strategies, including biomarker-defined populations, potential combination approaches, and future portfolio implications.
Develop global epidemiology, treatment-flow, and patient-segmentation models, revenue scenarios, sensitivity analyses, and commercial value assessments.
Collaborate with Clinical Development, Medical Affairs, HEOR, and Market Access on target populations, endpoints, therapy duration, standards of care, and evidence needed for adoption.
Work with Precision Medicine and Diagnostics on RAS/KRAS testing, KRAS G12D-defined populations, laboratory and referral workflows, accessibility, and the commercial implications of molecularly guided care.
Build a unified commercial understanding of relevant stakeholders and care settings, including oncologists, pancreatic surgeons, gastroenterologists, radiologists, pathologists, tumor boards, academic centers, and community settings.
Coordinate with first-line and metastatic teams, regional affiliates, and global brand teams to share insights and support launches.
Develop stage-gated global commercialization frameworks, value propositions, brand positioning, affiliate readiness, access and customer-pathway assumptions, and U.S. and global launch scenarios.
Monitor scientific milestones, competing programs, diagnostic adoption, treatment patterns, and commercial assumptions, and adjust strategic plans and forecasts as evidence and investment decisions evolve.
Guide cross-functional working teams, agencies, market research and analytics partners; communicate with senior leaders and governance forums; and apply digital and data-driven approaches.